Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCLAF1 and THRAP3 family member 3 (abbreviated BCLAF3) is a human protein-coding gene that, based on current annotations, is predicted to act as a DNA-binding protein and transcriptional coregulator[3][5][6]. It is a member of the THRAP3/BCLAF1 protein family, which is characterized by DNA binding and involvement in transcriptional regulation. While homologous proteins in this family (THRAP3 and BCLAF1) are well-established in RNA splicing, DNA damage response, and cancer biology[1][2][4], detailed functional and disease-specific studies on BCLAF3 itself are limited. No drug interactions or biomarker uses are currently described for BCLAF3, and it is not presently considered a therapeutic target. The protein is 711 amino acids in length in the human genome[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCLAF1 and THRAP3 family member 3 (BCLAF3).